MG53: Enhancing Tissue Performance and Repairing Damaged Tissue
T2020-129 , T2019-164, T2020-002, T2020-159, T2020-222: Using rhMG53 to treat conditions involving damaged tissue, including corneal repair, hepatic tissue injury, inflammatory bowel disease, and other tissue injury.
The Need
While MG53 is naturally present in skeletal and cardiac muscle, its levels are often insufficient to optimize tissue performance. Current treatments leveraging exogenous MG53 are therapeutically ineffective for conditions like multiple sclerosis, viral infections, radiation-induced tissue injury, and obesity. There is a critical need for innovative methods to enhance the functionality of otherwise healthy tissues, including skeletal muscle, cardiac muscle, kidney, neuronal, and corneal tissues, beyond just repair.
The Technology
Researchers at The Ohio State University have developed a therapeutic approach to enhancing performance of a variety of tissues by systemically administering recombinant human MG53 (rhMG53). The technology encompasses a variety of dosage forms, including biological and non-biological carriers, that either directly deliver MG53 to the target tissue or enable its expression within the target tissues. By leveraging viral vectors, autologous blood serum, and bioengineered hematopoietic stem cells, this method ensures efficient and targeted delivery of MG53, thereby significantly improving tissue function.
Commercial Applications
- Skeletal Muscle Performance: Enhances strength and endurance in healthy muscle tissues.
- Cardiac Muscle Function: Improves the performance of heart tissues, supporting overall cardiac health.
- Kidney Functionality: Boosts the performance of renal tissues, aiding in better filtration and waste removal.
- Corneal Health: Improves corneal tissue performance, potentially benefiting vision and eye health.
Benefits/Advantages
- Enhanced Tissue Function: Improves the performance of healthy tissues, not just repairing damage.
- Targeted Delivery: Utilizes advanced vectors and autologous serum for precise and efficient MG53 delivery.
- Versatile Dosage Forms: Offers multiple delivery methods, including viral vectors and bioengineered cells.
- Customizable Treatments: Allows for tailored therapy using autologous serum and bioengineered cells to meet specific patient needs.
Patent Applications Pending in US and Multiple Countries